Better Outcomes with Osilodrostat in Cushing Disease
Author Information
Author(s): John Newell-Price, Maria Fleseriu, Rosario Pivonello, Richard A. Feelders, Mônica R. Gadelha, André Lacroix, Przemysław Witek, Anthony P. Heaney, Andrea Piacentini, Alberto M. Pedroncelli, Beverly M. K. Biller
Primary Institution: University of Sheffield, Oregon Health & Science University, Università Federico II di Napoli, Erasmus Medical Center, Universidade Federal do Rio de Janeiro, Centre hospitalier de l’Université de Montréal, Medical University of Warsaw, University of California, Los Angeles, Recordati SpA, Recordati AG, Massachusetts General Hospital
Hypothesis
Does simultaneous normalization of late-night salivary cortisol and mean urinary free cortisol in patients with Cushing disease treated with osilodrostat lead to better clinical outcomes than controlling either parameter alone?
Conclusion
Normalizing both late-night salivary cortisol and mean urinary free cortisol in patients with Cushing disease treated with osilodrostat leads to improved long-term outcomes.
Supporting Evidence
- 85% of patients had uncontrolled cortisol levels at baseline.
- 48.6% achieved control of both cortisol levels after 72 weeks.
- Improvements in cardiovascular/metabolic parameters were greatest in patients with both cortisol levels controlled.
- Quality of life improved significantly in patients with controlled cortisol levels.
Takeaway
This study shows that for people with Cushing disease, getting both their nighttime and daily cortisol levels back to normal helps them feel better and stay healthier.
Methodology
Data from two phase III osilodrostat studies were pooled and analyzed, focusing on changes in cardiovascular/metabolic parameters, physical manifestations, and quality of life across different patient subgroups.
Potential Biases
Potential bias due to differences in study design and the primary endpoint focusing on mean urinary free cortisol normalization.
Limitations
The analysis had a small number of patients with only late-night salivary cortisol control and differences in osilodrostat exposure between studies.
Participant Demographics
Median age was 39 years, with 80.6% female and a high proportion having persistent or recurrent disease.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI for time to first normalization: LNSC 82.0 days, mUFC 35.0 days, both 335.0 days.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website